In slides for its investor day meeting, Myriad Genetics notes a 10%+ CAGR target for total revenue in 2024-2026 and states that the company targets “total revenue of over $1 billion in 2026.” “This revenue target includes modest contribution from planned new products and no contribution from future M&A,” the slides state. Myriad targets adjusted operating income of approximately $100M in 2026, or 10% of total revenue in 2026, the slides added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics to host investor day
- Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
- Myriad Genetics, Illumina achieve milestones in strategic partnership
- Myriad Genetics Issues 2022 Environmental, Social and Governance Report
- Myriad , MSK collaborate to study use of minimal residual disease testing
